Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -97.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -97.77% |
| Mar 31, 2026 | 325.17% |
| Dec 31, 2025 | -135.63% |
| Sep 30, 2025 | 32.96% |
| Jun 30, 2025 | 554.89% |
| Dec 31, 2024 | 72.18% |
| Sep 30, 2024 | -54.51% |
| Jun 30, 2024 | -150.32% |
| Mar 31, 2024 | 46.88% |
| Dec 31, 2023 | -406.84% |
| Sep 30, 2023 | 464.00% |
| Jun 30, 2023 | 91.39% |
| Mar 31, 2023 | -60.59% |
| Dec 31, 2022 | -52.53% |
| Sep 30, 2022 | -52.05% |
| Jun 30, 2022 | -69.99% |
| Mar 31, 2022 | 310.10% |
| Dec 31, 2021 | 614.84% |
| Sep 30, 2021 | 112.21% |
| Jun 30, 2021 | 1,045.07% |